Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—commonly used in treating type 2 diabetes and obesity—may offer new promise in treating AUD.

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.

Nearly all of the world’s top pharmaceutical companies are racing to develop new oral GLP-1 drugs. By enhancing the performance of oral dosing choices as a replacement for disliked injections ...

Drugmaker Eli Lilly (LLY 1.21%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...